18 results about "Drug Dissolution" patented technology

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

This utility model relates to the field of wastewater treatment technology, specifically to a drug dissolving device for wastewater treatment. The device includes a dissolving cylinder, which comprises a cylinder body. A top cover is fixedly connected to the upper end of the cylinder body, and a bottom plate is fixedly connected to the lower end. The top cover is equipped with a stirring mechanism and a feeding mechanism for quantitatively adding drugs. The bottom plate is equipped with an air blowing mechanism for introducing air into the dissolving cylinder, and a sealing mechanism for sealing the dissolving cylinder is located below the bottom plate. A water pipe for adding water to the dissolving cylinder is installed on the side wall of the cylinder body, and an electrically controlled valve is installed on the water pipe. In this utility model, an air pump is used to pump external air into an annular and radial pipes, and then discharges it into the water through air outlets on the annular and radial pipes, creating surging bubbles in the water. Compared to simply having a stirring mechanism, this device further enhances water flow, thereby significantly increasing the drug dissolving speed.

This utility model discloses a drinking water device for pig farming, relating to the field of pig farming technology. Specifically, it is a drinking water device for pig farming, including a drinker with a water storage device installed on the outside. The drinker has a first slot inside, and a drinker frame is installed in the first slot. A second slot is opened through the outer frame of the drinker, and a displacement device that can move up and down according to the water volume is installed at the bottom of the second slot. A spring plate assembly can drive a switch trigger assembly to move up and down according to the water volume. When moving, it can trigger a motor switch to start or stop the motor from injecting water. This allows water to be automatically injected when the pigs' drinking water is insufficient and automatically shut off when the water volume is sufficient, eliminating the need for manual water injection. The medication is placed in the storage tank of the injection device. While water is being injected, the injection device rotates, allowing for intermittent injection of medication without accumulation, which helps the medication dissolve.

The present application belongs to the field of natural medicine, and provides a valerian self-microemulsion drop pill and a preparation method thereof, which is prepared from the following components by weight: valerian volatile oil 20-40 parts, valerian extract powder 8-10 parts, oil phase 10-30 parts, emulsifier 40-80 parts, co-emulsifier 10-50 parts, and base 200-650 parts. The volatile oil and alcohol-soluble components of valerian are extracted, and are prepared into self-microemulsion together with oil ester, emulsifier and co-emulsifier, so as to increase the drug solubility, promote the absorption of the drug, and improve the bioavailability. Then, the self-microemulsion is solidified in the form of drop pill, so as to obtain the valerian self-microemulsion drop pill with high drug solubility, high bioavailability and good stability. By controlling the mass ratio of the base and the valerian self-microemulsion, the heating temperature of the drug-containing base, and the drop distance, the forming rate of the drop pill can reach more than 90%.

This invention discloses an anhydrous swallowable granule and its preparation method. The anhydrous swallowable granule comprises the following components: mesoporous silica-drug, filler, disintegrant, and binder, with the following weight percentages: mesoporous silica-drug 15%–40%, filler 45%–80%, disintegrant 0%–20%, and binder 1%–3%. This invention uses a suitable solvent to dissolve the drug and loads it into the mesoporous silica pores via solvent impregnation, forming a mesoporous silica-drug. This mesoporous silica-drug allows the drug molecules to exist in an amorphous or non-crystalline form and possesses relatively good powder properties. Further addition of filler, disintegrant, binder, and flavoring agent prepares a drug granule suitable for direct swallowing. This formulation has good taste and compliance, achieves complete dissolution within 5 minutes, and shows no detectable drug components in 3 mL of simulated saliva for at least 30 seconds. It can be swallowed directly, increasing medication compliance and safety for elderly and infant patients, and demonstrating good efficacy.

The invention relates to a grinding device for pharmacy. The grinding device comprises a supporting base, a tamping rod frame is connected to the supporting base, a grinding tank is arranged on the lower portion of the tamping rod frame, an electric secondary telescopic rod is connected to the upper portion of the tamping rod frame, a grinding block is connected to the telescopic end of the electric secondary telescopic rod, and a driving piece is connected between the tamping rod frame and the grinding tank. The technical scheme of the invention has the beneficial technical effects that the electric secondary telescopic rod is adopted to drive the grinding block to realize lifting, extruding and grinding, so that each medicine raw material can be in uniform contact with the extruding and grinding surface of the grinding block, the problem of non-uniform grinding caused by local accumulation and corner residues of medicines is effectively avoided, and the granularity consistency of final ground products is ensured. The synergistic grinding mode is especially suitable for scenes with high requirements on the fineness of medicine powder in pharmaceutical research and preparation production, high-quality raw materials can be provided for subsequent medicine dissolution, mixing and preparation forming, and the dissolution rate and the medicine effect stability of the medicine are indirectly guaranteed.

The application belongs to the technical field of spectral analysis, and particularly relates to a spectral detection method and system for drug dissolution, which comprises the following steps: S1, acquiring real-time spectral data of a dissolution process, and calculating a dynamic scattering intensity index representing the environmental turbidity degree according to the full-spectrum average absorbance, the spectral first-order differential variance, the low-frequency energy and the total energy; S2, adaptively adjusting a penalty factor of a variational mode decomposition algorithm based on the dynamic scattering intensity index, and decomposing the real-time spectral data into multiple intrinsic mode functions by using the adjusted variational mode decomposition algorithm; combining spectral information divergence and mode center frequency to construct an effectiveness weight, and performing weighted summation on the multiple intrinsic mode functions according to the effectiveness weight to obtain a net analysis signal. The application can dynamically adjust the algorithm strategy according to the physical state of the dissolution medium, and realizes high-precision online monitoring of the drug dissolution in a complex environment.

The present invention relates to an orally disintegrating tablet manufactured by a direct compression method comprising paroxetine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orally disintegrating tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. The present invention also relates to the process for preparing the said solid pharmaceutical composition.

The present application belongs to the technical field of medical apparatus and instruments, in particular to a tumor nursing dispensing device and its using method, aiming at solving the problem of liquid back-spraying and poor dissolving effect of the existing dispensing method, the device comprises a base, a bearing tray, a lifting arm and an injection mechanism, the injection mechanism comprises a sliding groove and a pressing plate, the outer wall of the piston cylinder is provided with a back-spraying prevention mechanism, which comprises a fixing ring and an outer sleeve, when the needle is pierced, the positive pressure generated in the bottle is introduced into the air bag to absorb the pressure and prevent the liquid from back-spraying when the needle is pulled out, a shaking mechanism is arranged between the base and the bearing tray, comprising a metal ring, a vertical rod and a supporting mechanism, the mechanism can make the bearing tray produce a conical swing trajectory similar to nutation while driving the bearing tray to rotate, forming liquid vortex in the medicine bottle to gently dissolve the freeze-dried powder of chemotherapy, avoiding the generation of harmful bubbles, the device can effectively reduce the risk of liquid back-spraying and improve the uniformity of drug dissolution and the accuracy of dosage.

This application belongs to the field of pharmaceutical devices. It provides a multi-stage accelerated dissolution device and method, comprising: at least one cup assembly, the cup assembly including at least one cup body, the cup assembly on a first support plate, the first support plate connected to a second support plate, a first power device driving the second support plate to rotate, a second power device driving the first support plate to rotate, and a third power device driving the cup body to rotate. This three-stage acceleration can be freely combined, allowing for both slow adjustment of the cup body position and multi-stage rapid acceleration for drug dissolution. The multi-stage accelerated pre-dissolution device and solution preparation method of this application, by setting multiple sets of multi-stage transmission structures, allows the cup body to both rotate and revolve around an axis located outside its body, thereby achieving better dissolution results and avoiding foaming caused by vibration.

The utility model discloses a kind of be applied to the comminuting device of crude drug, including base, control mechanism is installed in the upper portion of base, the control mechanism is connected with comminuting mechanism;Motor drive screw feeder feeds and comminutes to the comminuting mechanism.The control mechanism includes the control box being installed in the upper portion of base, switch is arranged on the control box, for starting or closing the comminuting mechanism;It also includes external frequency converter and control system, the frequency converter and the control system are connected with the comminuting mechanism and the control box by communication module or cable.The product granularity of device after grinding is finer, smallest can make material evenly reach 200 microns, can improve drug dissolution rate and bioavailability, enhance preparation uniformity and stability, expand drug dosage form and application range, can satisfy the demand of different customer groups, increase product added value and its sales volume.

This invention discloses a co-treated product of magnesium stearate and sodium dodecyl sulfate and its preparation method, belonging to the field of pharmaceutical excipient technology. The co-treated product is composed of magnesium stearate and sodium dodecyl sulfate in a mass ratio of 94:6, with a drying loss ≤5%, a particle size D50 of 5-30 μm, and a bulk density of 0.05-0.30 g / cm³. 3 The preparation method includes: first, synthesizing magnesium stearate with specific physicochemical properties; then, mixing it with sodium dodecyl sulfate in an ethanol-water solution in a certain proportion to form a slurry; and finally, spray drying after dispersion treatment. This co-treated compound solves the problems of uneven physical mixing and poor batch stability. In tablet applications, it exhibits excellent lubricity and significantly promotes tablet disintegration and drug dissolution, effectively mitigating the "over-lubricating" effect of magnesium stearate. The overall performance of tablet hardness and disintegration time is superior to that of magnesium stearate alone and its physical mixtures.

Co-crystals comprising an API and a molecular scaffold comprising a saccharide are described herein. The co-crystals can be used to improve drug solubility and bioavailability, tailor API release profiles, achieve controlled hydrophilicity and lipophilicity, enhance stability, improve taste and palatability, reduce the need for chemical modifications and process steps, and are applicable to a wide range of APIs. In various embodiments, the APIs include, but are not limited to, stimulants, antibiotics, antiviral drugs, antifungal drugs, and anticancer drugs. The co-crystals provided herein can be prepared by a variety of different methods, and in several embodiments, a variety of APIs can be co-crystallized with a molecular scaffold comprising a saccharide.

This invention relates to the field of pharmaceutical formulation technology, and discloses a rebamipide tablet formulation and its preparation process. The formulation, by weight, mainly comprises 100 parts rebamipide, 5 to 15 parts L-arginine, 2 to 8 parts poloxamer 188, 10 to 20 parts hydroxypropyl cellulose, and excipients such as low-substituted hydroxypropyl cellulose and microcrystalline cellulose. The preparation process includes: preparing a composite binder solution containing L-arginine, poloxamer 188, and hydroxypropyl cellulose at 10°C to 15°C; adding rebamipide and cold-curing to obtain a suspension; subsequently, during fluidized bed granulation, by adjusting the absolute humidity and temperature of the inlet air in stages, sequentially performing high-humidity delayed drying and spreading followed by dehumidification and temperature-increasing curing. This invention prevents hydrophobic drug agglomeration and nozzle clogging through low-temperature processing; the in-situ crystallization of L-arginine creates a weakly alkaline microenvironment, significantly improving the drug dissolution rate in acidic media; and achieving high granulation yield and batch-to-batch uniformity of content.

This invention relates to choline amino acid ionic liquid microemulsions, their preparation methods, and applications. It belongs to the fields of ionic liquid microemulsions and pharmaceutical formulations. The preparation method includes: dissolving amino acids and choline in water or ethanol, mixing them under heating with shaking, removing the solvent by rotary evaporation, filtering unreacted amino acids to obtain a choline amino acid ionic liquid; mixing a surfactant with isopropyl myristate in a specific ratio, adding the ionic liquid dropwise to the mixture while continuously stirring until the liquid becomes clear and transparent. The choline amino acid ionic liquid microemulsion provided by this invention has good transdermal absorption capacity and can significantly increase drug solubility. Compared to water, it increases the solubility of hydrophobic methotrexate by 3.2–10.5 times and the solubility of doxorubicin hydrochloride by 1.3–2 times. It also has strong inhibitory and bactericidal effects against Staphylococcus aureus, good biocompatibility, and can be used as a carrier for transdermal drug delivery.

This invention discloses a method for improving the drug-loading performance of vesicles, including systematic optimization of the drug loading process. It employs a synergistic combination of thin-film dispersion-ultrasound and emulsification-solvent evaporation to prepare drug-loaded nanoparticles. First, the vesicle carrier material and drug are dissolved and then rotary evaporated to form a uniform thin film. A hydrated solvent is added for incubation to obtain a hydrated liquid. The hydrated liquid is then ultrasonically treated to promote drug dispersion. Subsequently, an emulsifier is added to form a primary emulsion, which is then mixed and emulsified with the aqueous phase. Stirring allows the organic solvent to slowly evaporate, enabling the carrier material to self-assemble into vesicle structures. Finally, uniformly dispersed drug-loaded nanoparticles are obtained. This invention uses a synergistic combination of thin-film dispersion-ultrasound and emulsification-solvent evaporation, rather than a single process selection. The two processes complement each other. By first preparing the thin film and hydrating it, then ultrasonically dispersing it, and finally emulsifying and evaporating it to form the vesicles, the problem of uneven drug dispersion and localized aggregation in traditional single-process methods is effectively solved.

The application discloses a preparation method of inositol nicotinate tablets and belongs to the technical field of pharmaceutical preparations. The method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase with a water phase, spray drying the drug emulsion powder, and coating the drug emulsion powder with modified chitosan and then directly compressing the drug emulsion powder with excipients. The inositol nicotinate is uniformly dispersed in the mixed oil, so that the drug content uniformity is maintained in the subsequent process, the solid particles are adsorbed on the surface of the drug-containing oil droplets through the emulsification technology, and the drug components are protected. The coating components are reasonably designed, the drug is released at a fixed point, the anti-pressing capacity is endowed, and the drug can be directly compressed. The drug particles after coating are mixed with excipients and then directly compressed, so that the process is simplified, and the coating structure of the drug particles is protected. The inositol nicotinate tablets prepared by the method have stable drug dissolution, good taste and small stimulation to gastric mucosa.